Tech Company Financing Transactions
AvenCell Therapeutics Funding Round
AvenCell Therapeutics, operating out of Watertown, secured $112 million in investment from Novo Holdings, Blackstone and Eight Roads.
Transaction Overview
Company Name
Announced On
10/22/2024
Transaction Type
Venture Equity
Amount
$112,000,000
Round
Series B
Investors
Novo Holdings (Lead Investor) (Michael Bauer)
Proceeds Purpose
The Watertown, Massachusetts-based company intends to use the funds to demonstrate that its platform can produce "switchable" CAR-T cells that can be turned "off" or "on" even after they have been administered.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
500 Forge Road
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
AvenCell Therapeutics, Inc. was recently launched by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics, Inc. and incorporated the clinical-stage biopharmaceutical company GEMoaB GmbH, now named AvenCell Europe GmbH.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrew Schiermeier
Chief Financial Officer
Babar Ghias
Chief Medical Officer
Tapan Maniar
Chief Scientific Officer
Armin Ehninger
Chief Technical Officer
Marc Cartellieri
VP - Bus. Development
Manfred Klevesath
VP - Finance
Andrea Kistner
VP - Human Resources
Jill Rogers
VP - Operations
Susan Buttler
VP - Operations
Markus Orchowski
VP - R & D
Reynald Lescarbeau
Browse more venture capital transactions:
Prev: 10/22/2024: Turnover Labs venture capital transaction
Next: 10/22/2024: Pantheon AI venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs